Key result
CYP2C19 poor metabolizer status was associated with a higher risk of myocardial infarction and death in elderly patients undergoing PCI.
Why the study?
Elderly PCI patients face higher ischemic and bleeding risks, but few studies have reported how genetic variants affect their clinical outcomes.
Do CYP2C19 and P2Y12 G52T genetic variants predict clinical outcomes in elderly patients (≥75 years) undergoing PCI?
Cohort (n=811)
Yes
Do CYP2C19 and P2Y12 G52T genetic variants predict clinical outcomes in elderly patients (≥75 years) undergoing PCI?
In elderly patients undergoing PCI, CYP2C19 poor metabolizer status predicts ischemic events and death, while the P2Y12 G52T TT genotype predicts major bleeding.
Answers are grounded in this paper and cite their sources.
May identify higher ischemic risk in elderly CYP2C19 poor metabolizers post-PCI; leaves open whether genotyping improves outcomes.
Elderly patients treated with percutaneous coronary intervention (PCI) have a higher risk of both ischemic and bleeding complications than younger patients. However, few studies have reported how genetic information of elderly patients treated with PCI affects clinical outcomes. We investigated the impact of genetic variants on clinical outcomes in elderly patients. Correlations between single-nucleotide polymorphisms (CYP2C19 and P2Y12 receptor gene G52T polymorphism) and clinical outcomes were analyzed in 811 elderly patients (≥75 years of age) from a prospective multicenter registry. The primary endpoint was a composite of myocardial infarction and death. Secondary endpoints were an individual event of death, cardiac death, myocardial infarction, stent thrombosis, target lesion revascularization, stroke, and major bleeding (Bleeding Academic Research Consortium ≥3). Regarding CYP2C19, patients with poor metabolizers had a significantly higher risk for the primary endpoint (hazard ratio [HR] 2.43; 95% confidence interval [95% CI] 1.12-5.24; p=0.024) and secondary endpoints (death and cardiac death). Regarding P2Y12 G52T, the TT group had a significantly higher occurrence of major bleeding than the other groups (HR 3.87; 95% CI 1.41-10.68; p=0.009). In conclusion, poor metabolizers of CYP2C19 and TT groups of P2Y12 G52T may be significant predictors of poor clinical outcomes in elderly patients.
No takes yet. Share an insight, caveat, or question.
Cha et al. (2021) conducted a cohort in percutaneous coronary intervention (n=811). CYP2C19 poor metabolizer status and P2Y12 G52T TT genotype vs. Other genotypes was evaluated on composite of myocardial infarction and death (HR 2.43, 95% CI 1.12-5.24, p=0.024). CYP2C19 poor metabolizer status was associated with a higher risk of myocardial infarction and death in elderly patients undergoing PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: